论文部分内容阅读
基于意大利的一项研究,吡考酰胺(Picota-mide,PT)在减少罹患外周动脉疾病(PAD)的糖尿病患者的死亡方面较阿司匹林更为有效。此前的研究显示,阿司匹林预防糖尿病患者的血管性事件可能不及对其他疾病人群的预防效果;但来自于意大利博洛尼亚大学的 Sergio Coccheri 教授及其同事对 PT——血栓素 A2合酶与血小板血栓素(内过氧化物酶受体的一种双重抑制剂)有可能比阿司匹林更有效的理论机制进行了研究。
Based on a study in Italy, Picota-mide (PT) is more effective than aspirin in reducing the death of diabetic patients with peripheral arterial disease (PAD). Previous studies have shown that aspirin may be less effective in preventing vascular events in people with diabetes than those in other disease populations; however, Professor Sergio Coccheri from the University of Bologna, Italy, and colleagues evaluated the association of PT- thromboxane A2 synthase with platelet thromboxane A dual inhibitor of endoperoxidase receptors) is likely to be more effective than aspirin.